Galapagos « Terug naar discussie overzicht

quote:

mooiweer schreef op 13 september 2018 15:56:

[...]

Alweer dit lees je vaker en een paar dagen later nog goedkoper.

quote:

jo2018 schreef op 13 september 2018 15:45:

analisten zeggen tussen 110 en 122.maar ja bij ab inbev zeiden ze tussen 100 en 120 ging in 10 dagen van 88 naar 75 hahahahaha werken die analisten
voor die bedrijven of zo???

quote:

robbie123 schreef op 13 september 2018 15:59:

Goedzo sindicaat hijsen die boel

quote:

Ron Kerstens schreef op 13 september 2018 16:04:

Zo maar een vraag; Bestaan er geen scrips waarmee je alleen reacties ziet die van belang/interesse zijn en alle shitzooi blocken ?

quote:

Ron Kerstens schreef op 13 september 2018 16:04:

Zo maar een vraag; Bestaan er geen scrips waarmee je alleen reacties ziet die van belang/interesse zijn en alle shitzooi blocken ?

quote:

Ron Kerstens schreef op 13 september 2018 16:04:

Zo maar een vraag; Bestaan er geen scrips waarmee je alleen reacties ziet die van belang/interesse zijn en alle shitzooi blocken ?

quote:

Beurskingpin schreef op 13 september 2018 16:22:

Sensitivity analysis suggests positive risk/reward with a bull case of €155 (c.50%
upside potential) and a bear case of €75 (c.30% downside potential)
We have performed a sensitivity analysis on our base case EmV assessing a range of
outcomes for filgotinib sales and approval of pipeline projects. In our Bull case
scenario we remove the risk adjustment for filgotinib in RA (+€6.8 per share),
increase our peak filgotinib RA sales by €500m (+€13.5 per share) and remove the
risk adjustments on filgotinib in both UC and PsA (+€16.1 per share), seeing as these
are the indications in which Pfizer's Xeljanz is already approved. This leads to a bull
case EmV of €155, which offers c.50% upside to current levels. Overall, our bull
case factors in €4.5bn of risk adjusted filgotinib sales (vs. base case €3.2bn).

Aldus JP Morgan.

quote:

Beurskingpin schreef op 13 september 2018 16:22:

Sensitivity analysis suggests positive risk/reward with a bull case of €155 (c.50%
upside potential) and a bear case of €75 (c.30% downside potential)
We have performed a sensitivity analysis on our base case EmV assessing a range of
outcomes for filgotinib sales and approval of pipeline projects. In our Bull case
scenario we remove the risk adjustment for filgotinib in RA (+€6.8 per share),
increase our peak filgotinib RA sales by €500m (+€13.5 per share) and remove the
risk adjustments on filgotinib in both UC and PsA (+€16.1 per share), seeing as these
are the indications in which Pfizer's Xeljanz is already approved. This leads to a bull
case EmV of €155, which offers c.50% upside to current levels. Overall, our bull
case factors in €4.5bn of risk adjusted filgotinib sales (vs. base case €3.2bn).

Aldus JP Morgan.

quote:

Beurskingpin schreef op 13 september 2018 16:22:

Sensitivity analysis suggests positive risk/reward with a bull case of €155 (c.50%
upside potential) and a bear case of €75 (c.30% downside potential)
We have performed a sensitivity analysis on our base case EmV assessing a range of
outcomes for filgotinib sales and approval of pipeline projects. In our Bull case
scenario we remove the risk adjustment for filgotinib in RA (+€6.8 per share),
increase our peak filgotinib RA sales by €500m (+€13.5 per share) and remove the
risk adjustments on filgotinib in both UC and PsA (+€16.1 per share), seeing as these
are the indications in which Pfizer's Xeljanz is already approved. This leads to a bull
case EmV of €155, which offers c.50% upside to current levels. Overall, our bull
case factors in €4.5bn of risk adjusted filgotinib sales (vs. base case €3.2bn).

Aldus JP Morgan.